Method of inhibiting clostridium difficile by administration of oritavancin
View Patent ↗Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.
1. A method of inhibiting outgrowth of a C. difficile spore, comprising contacting a C. difficile spore with a glycopeptide antibiotic in an amount sufficient to inhibit outgrowth of a C. difficile spore, thereby inhibiting outgrowth of a C. difficile spore, wherein the glycopeptide antibiotic is oritavancin, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or a mixture thereof.
2. A method of inhibiting outgrowth of a C. difficile spore and growth of a vegetative form of C. difficile , comprising contacting a C. difficile spore and a vegetative form of C. difficile with a glycopeptide antibiotic in an amount sufficient to inhibit outgrowth of a C. difficile spore and growth of a vegetative form of C. difficile , thereby inhibiting outgrowth of a C. difficile spore and growth of a vegetative form of C. difficile , wherein the glycopeptide antibiotic is oritavancin, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or a mixture thereof.
3. The method of claim 1 , wherein C. difficile is contacted in vitro, in vivo or ex vivo.
4. The method of claim 2 , wherein C. difficile is contacted in vitro, in vivo or ex vivo.
5. A method of treating a C. difficile infection in a subject, comprising administering a therapeutically effective amount of a glycopeptide antibiotic to a subject having a C. difficile infection, wherein said treatment inhibits outgrowth of a C. difficile spore, thereby treating a C. difficile infection in a subject.
6. A method of treating a C. difficile infection in a subject, comprising administering a therapeutically effective amount of a glycopeptide antibiotic to a subject having a C. difficile infection, wherein said treatment inhibits outgrowth of a C. difficile spore and growth of a vegetative form of C. difficile , thereby treating a C. difficile infection in a subject.
7. The method of claim 5 or 6 , wherein the glycopeptide antibiotic is in the form of a pharmaceutical composition comprising the glycopeptide antibiotic and a pharmaceutically acceptable carrier or diluent.
8. The method of claim 5 or 6 , wherein said administering is via intravenous administration or oral administration.
9. The method of claim 5 or 6 , wherein said administering is via oral administration.
10. The method of claim 5 or 6 , wherein the therapeutically effective amount of the glycopeptide antibiotic is between about 5 and 30 mg/kg body weight.
11. The method of claim 10 , wherein said administering is BID for four days.
12. The method of claim 5 or 6 , wherein C. difficile is contacted in vitro, in vivo or ex vivo.